p-Nitro benzamidoxime (DMZ)
Nitro amidoxime intermediate aligned to Diminazene synthesis with controlled hydroxylamine residues (CAS 1613-86-1). End use: Diminazene.
Product overview
Rraynex catalogues p-Nitro benzamidoxime (DMZ) under veterinary intermediates.
Pharmaceutical intermediates are compounds produced at a defined stage of an API synthesis route and supplied to API manufacturers for the following reaction steps.
Pharmaceutical applications
- Downstream API synthesis.
- Route development and scale-up by API manufacturers.
Product specifications
- Product
- p-Nitro benzamidoxime (DMZ)
- Form
- Intermediate
- Therapeutic category
- Veterinary Intermediate
- CAS number
- 1613-86-1
- Strength
- Agreed per project — share your target strength in the enquiry
- Grade
- Custom / On Request
- Pack size
- 5/25 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies p-Nitro benzamidoxime (DMZ) to pharmaceutical manufacturers, formulation developers and CDMOs in 5/25 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all intermediates Manufacturing capabilities